Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

被引：0
|
作者：
Krieger, Laurence [1 ]
Fizazi, Karim [2 ]
Shore, Neal [3 ]
Tammela, Teuvo L. [4 ,5 ]
Ulys, Albertas [6 ]
Vjaters, Egils [7 ]
Polyakov, Sergey [8 ]
Jievaltas, Mindaugas [9 ]
Luz, Murilo [10 ]
Alekseev, Boris [11 ]
Kuss, Iris [12 ]
Le Berre, Marie-Aude [13 ]
Petrenciuc, Oana [14 ]
Snapir, Amir [15 ]
Sarapohja, Toni [15 ]
Smith, Matthew R. [16 ]
机构：
[1] Northern Canc Inst, St Leonards, NSW, Australia
[2] Univ Paris Sud, Inst Gustave Roussy, Paris, France
[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[4] Tampere Univ Hosp, Tampere, Finland
[5] Tampere Univ, Tampere, Finland
[6] NCI, Bethesda, MD 20892 USA
[7] Stradins Clin Univ Hosp, Riga, Latvia
[8] NN Alexandrov Natl Canc Ctr Belarus, Liasny, BELARUS
[9] Lithuanian Univ Hlth Sci, Med Acad, Kaunas, Lithuania
[10] Hosp Erasto Gaertner, Curitiba, Parana, Brazil
[11] Minist Hlth Russian Federat, Natl Med Res Radiol Ctr, Moscow, Russia
[12] Bayer AG, Leverkusen, Germany
[13] Bayer Healthcare SAS, Leverkusen, Germany
[14] Bayer Healthcare, Leverkusen, Germany
[15] Orion Corp Orion Pharma, Espoo, Finland
[16] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs27
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [31] Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use
    Yang, Cheng-Kuang
    Cha, Tai -Lung
    Chang, Yen-Hwa
    Huang, Shu-Pin
    Lin, Jen-Tai
    Wang, Shian-Shiang
    Huang, Chao-Yuan
    Pang, See-Tong
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2023, 122 (04) : 299 - 308
  • [32] Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI)
    Matsumoto, Kazuhiro
    Kosaka, Takeo
    Takeda, Toshikazu
    Fukumoto, Keishiro
    Yasumizu, Yota
    Tanaka, Nobuyuki
    Morita, Shinya
    Mizuno, Ryuichi
    Asanuma, Hiroshi
    Oya, Mototsugu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (08) : 1198 - 1203
  • [33] Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
    Alkhudair, Nora A.
    SAUDI PHARMACEUTICAL JOURNAL, 2019, 27 (03) : 368 - 372
  • [34] Metastasis-free survival as a predictor of overall survival in non-metastatic castration-resistant prostate cancer.
    Gagnon, Richard
    Alimohamed, Nimira S.
    Batuyong, Eugene
    Chow, Alyssa
    Lee-Ying, Richard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [35] Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Smith, Matthew Raymond
    Mehra, Maneesha
    Nair, Sandhya
    Lawson, Joe
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
    Jang, Ho Seong
    Koo, Kyo Chul
    Cho, Kang Su
    Chung, Byung Ha
    YONSEI MEDICAL JOURNAL, 2016, 57 (05) : 1070 - 1078
  • [37] Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial
    Fizazi, Karim
    Shore, Neal D.
    Smith, Matthew
    Ramos, Rodrigo
    Jones, Robert
    Niegisch, Guenter
    Vjaters, Egils
    Wang, Yuan
    Srinivasan, Shankar
    Sarapohja, Toni
    Verholen, Frank
    EUROPEAN JOURNAL OF CANCER, 2023, 192
  • [38] First-Line Treatment After the Failure of Androgen Deprivation Therapy for Non-Metastatic, Castration-Resistant Prostate Cancer Men
    Zhu, Yuhong
    Yang, Gaojie
    Ding, Yangyang
    Wu, Lifen
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2022, 18 (04) : 714 - 720
  • [39] Treatment duration and long-term safety and tolerability of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study
    Shore, Neal
    Boegemann, Martin
    Luz, Murilo
    Ulys, Albertas
    Srinivasan, Shankar
    Kurland, Etah
    Fizazi, Karim
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 83 - 83
  • [40] Interpreting the impact of apalutamide on overall survival among patients with non-metastatic castration-resistant prostate cancer
    McCaw, Z. R.
    Wei, L. -J.
    Ludmir, E. B.
    ANNALS OF ONCOLOGY, 2020, 31 (03) : 438 - 440
12345